Search clinical trials for: Elective ambulatory minor shoulder surgery

Total 37781 results

Ciusss de L'Est de l'Île de Montréal

Recruiting

Dexmedetomidine Added to Ropivacaine Single Shot vs Continuous Interscalene Nerve Block (DEXBIB)

Shoulder Pain | Anesthesia | Post Operative Pain

Canada
Phelps, Paul, M.D.
University of California, San Francisco

Completed

A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain

Shoulder Pain

United States
Affiliated Hospital of Jiaxing University

Recruiting

Postoperative Analgesic Effect of Infraspinatus-teres Minor Inter-fascial Block in Patients Undergoing Shoulder Surgery

Shoulder Pain

China
University of Michigan

Recruiting

Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: (PROTECT)

Surgery | Acute Pain

United States
Foundation for Orthopaedic Research and Education

Recruiting

Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery (CBDS)

Post-operative Pain

United States
University Hospital, Lille

Recruiting

Assessment of the Aromatherapy to Alleviate Peri Operative Anxiety in Ambulatory Elective Upper Limb Surgery Under Loco-regional Anesthesia (AROMA)

Anxiety

France
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, South Africa
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Canada, Ireland, Peru, South Africa
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Ann Arbor Stage II Non-Hodgkin Lymphoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Carcinoid Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.

Active, not recruiting

S0820, Adenoma and Second Primary Prevention Trial (PACES)

Colorectal Neoplasms

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931)

Kidney Cancer

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group

Active, not recruiting

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Stage II Breast Cancer | Stage IIIA Breast Cancer

United States, Canada, Puerto Rico
Rush University Medical Center

Active, not recruiting

Safety of Driving After Minor Surgery With Monitored Anesthesia Care (MACDrive)

Minor Surgical Procedures With Monitored Anesthesia Care | Driving Performance After Minor Ambulatory Surgery

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Active, not recruiting

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216)

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Metastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditions

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics...

Active, not recruiting

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States, Canada, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
Jessa Hospital

Completed

Evaluation of the Added Value of Metamizole to Standard Postoperative Treatment After Ambulant Shoulder Surgery (Metamizole003)

Postoperative Pain | Analgesia | Surgery

Belgium
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Breast Cancer

United States, Puerto Rico
Kuopio University Hospital

Completed

Implementation of 23 Hour Surgery Model in a Tertiary Hospital (Herko)

Ovarian Cysts | Shoulder Impingement Syndrome | Appendicitis | Cholecystolithiasis | Laparoscopy | Ambulatory Surgical Procedures | Neurosurgery | Ambulatory Surgery | Gynecologic Surgical Procedures

Finland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
L'Institut de Recherche en Chirurgie Orthopédique...

Completed

Comparison of Follow-up by Mobile App or Paper Questionnaire of Patients Undergoing Rotator Cuff Surgery (OFUE)

Rotator Cuff Injuries

France
Pfizer

Terminated

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation (STRIVE)

Staphylococcal Vaccine

United States, Spain, United Kingdom, Canada, France, Japan, Germany, Hungary, Austria, Bulgaria, Sweden
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
Central Jutland Regional Hospital
Aarhus University Hospital; University of Aarhus; Regional Hospital West Jutland

Completed

Reducing Shoulder Complaints in Employees With High Occupational Shoulder Exposures

Shoulder Pain

Denmark
Orthopaedic & Neurosurgery Specialists

Completed

Interscalene Block With and Without Liposomal Bupivacaine in Shoulder Surgery

Postoperative Pain | Rotator Cuff Tear

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Duke University

Withdrawn

Optimal Volume, Rate, and Interval of Bolus Nerve Catheters for Shoulder Surgery

Pain

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
State University of New York at Buffalo

Withdrawn

Changes in Anthropometry Following Ambulatory Orthopaedic Surgery (CAS)

Shoulder Surgery | Knee Surgery

United States
Centre Hospitalier Universitaire de Nīmes

Unknown

Multimodal Analgesia Strategies After Major Shoulder Ambulatory Surgery (Shoulder1)

Tendon Injuries

France
University of Manitoba

Completed

Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery

Pain, Postoperative | Brachial Plexus Block | Ambulatory Surgical Procedures | Shoulder Joint Disorder

Canada
National Cancer Institute (NCI)

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States

Search clinical trials for: Elective ambulatory minor shoulder surgery

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations